Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Sionna Therapeutics, Inc.NASDAQ: SION
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$84K, compared with $301K a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -127.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 540K USD
- Year-over-year change
- +46.7%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 540K | +46.7% |
| FY2024 | 2024-12-31 | 368K | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (16K) | — |
Accumulated OCI vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 Accumulated OCI of -$84K is the 4th highest of the 11 companies compared; the peer median is -$232K.
- Its year-over-year change of -127.9% is the 7th highest of 9, against a peer median of -55.7%.
- Accumulated OCI amounts to 0.0% of total assets for SION, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.38M | +179266.7% | +208.6% | 1.4% | |
| Mar 2026 | $576K | -84.7% | — | 0.1% | |
| Mar 2026 | -$24K | +4.0% | — | 0.0% | |
| Mar 2026 | -$84K | -127.9% | — | 0.0% | |
| Mar 2026 | -$124K | -788.9% | — | 0.0% | |
| Mar 2026 | -$135K | — | — | 0.0% | |
| Sep 2026 | -$329K | -108.7% | +42.2% | 0.0% | |
| Jun 2026 | -$403K | -176.5% | — | 0.1% | |
| Sep 2026 | -$467K | — | — | 0.1% | |
| Sep 2026 | -$3.42M | -26.8% | — | 0.2% | |
| Sep 2026 | -$6.66M | -10.1% | — | 0.6% | |
| Peer median (excluding SION) | -$232K | -55.7% | +125.4% | 0.1% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.